Primary object index
Interventions
Six evidence records across prescription medication, supplement ingredients, and dietary patterns. Browse by object, not by hype, ranking, or product category.
Semaglutide
Randomized obesity trials show large average weight reductions, while treatment context, tolerability, discontinuation, and long-term use remain essential to interpretation.
Tirzepatide
SURMOUNT-1 found substantial mean weight reductions across randomized tirzepatide groups, with a dose-group gradient and gastrointestinal adverse events.
Metformin
Metformin has strong evidence for diabetes prevention in selected high-risk adults, but it is not equivalent to modern obesity pharmacotherapy and weight effects are usually modest.
Berberine
Human trials and meta-analyses report mixed, generally small anthropometric effects. Product quality and study heterogeneity materially limit confidence.
Psyllium / soluble fiber
Psyllium has plausible satiety and metabolic effects, but pooled weight estimates vary substantially with trial selection, population, and intervention design.
High-protein dietary intervention
Higher-protein patterns can support weight-loss maintenance in some randomized settings, but the effect depends on energy balance, adherence, comparator diet, and population.